In the highest-security boardroom of Aetheris Medical Holdings, tension crackled in the air like static electricity.
The ten most powerful pharmaceutical CEOs in Panterra gathered around a sleek black glass table, their faces illuminated by the cold glow of holographic schematics.
Displayed were the AMHP-9 Emerald Rebirth Pod, VitaCore Emerald Liquid, and alarming market-crash projections triggered by the NanoGel EM1 QuickPatch.
The atmosphere was thick with an unsettling mix of ozone and quiet panic.
As they sat there, it was clear: these leaders were not just business moguls; they were titans of an industry worth hundreds of trillions of Unicreds.
Yet today, their expressions betrayed a rare vulnerability, gloom etched into every furrowed brow, eyes glinting with icy resolve.
Darius Veyne, the venerable CEO of Aetheris Medical Holdings and its oldest member at nearly two centuries old, drummed a slow, ominous rhythm on the table.
